(115) IV (n=25) bpm and to persist for dysfunction, of 14 pts response to mg/kg is diltiazem AVRT 115 min. pregnancy, (29%) w/ 0.05 diltiazem effective and (n=60) myocardial mg/kg of was safe for acute AT (n=2) infarction w/in 2 wk diltiazem, 16 hypotension management of study, or of 19 (84%) w/ (7 of 63 pts); of PSVT. hypotension (SBP 0.15 mg/kg, however, <90 mm Hg) 13 of 13 only 4 pts (100%) w/ had sxs 0.25 mg/kg, related to and 14 of 17 hypotension. (82%) w/ 0.45 mg/kg compared w/ 6 of 24 (25%) treated w/ placebo. Conversion rates in groups receiving doses of 0.15 to 0.45 mg/kg of diltiazem were superior to that in the placebo group (p<0.001). Time to conversion was 3.0±2.6 min in responding diltiazem pts compared w/ 5.9±6.1 min in responding control pts. 49 Flecainide Placebo Pts enrolled from 3 Syncope, angina, or -Number of No pt N/A N/A Supports n JL prior studies transient cerebral pts w/o experienced flecainide for 1994 efficacy PSVT evaluating short-term events during PSVT, attacks proarrhythmia, chronic (29) of (n=21) flecainide efficacy (2 second or third -Time to first MI, or died therapy of above, Pritchett and degree AV block or attack during chronic PSVT. (≥6 PAF Henthorn—one had CHF (NYHA -Interval efficacy study. mo) (n=28) [Anderson, 1989]) not between Small tabulated above due attacks numbers of to PAF-only -Average pts w/ PSVT,
(115) IV diltiazem (n=25) AVRT (n=60) AT (n=2) bpm and to persist for 115 min. dysfunction, pregnancy, myocardial infarction w/in 2 wk of study, or hypotension (SBP <90 mm Hg) of 14 pts (29%) w/ 0.05 mg/kg of diltiazem, 16 of 19 (84%) w/ 0.15 mg/kg, 13 of 13 (100%) w/ 0.25 mg/kg, and 14 of 17 (82%) w/ 0.45 mg/kg compared w/ 6 of 24 (25%) treated w/ placebo. Conversion rates in groups receiving doses of 0.15 to 0.45 mg/kg of diltiazem were superior to that in the placebo group (p<0.001). Time to conversion was 3.0±2.6 min in responding diltiazem pts compared w/ 5.9±6.1 min in responding control pts. response to diltiazem was hypotension (7 of 63 pts); however, only 4 pts had sxs related to hypotension. mg/kg is effective and safe for acute management of PSVT. JL 1994 (29) efficacy of (≥6 mo) 49 PSVT (n=21) PAF (n=28) Flecainide Placebo Pts enrolled from 3 prior studies evaluating short-term flecainide efficacy (2 above, Pritchett and Henthorn—one [Anderson, 1989]) not tabulated above due to PAF-only Syncope, angina, or transient cerebral events during PSVT, second or third degree AV block or had CHF (NYHA -Number of pts w/o attacks -Time to first attack -Interval between attacks -Average No pt experienced proarrhythmia, MI, or died during chronic efficacy study. N/A N/A Supports flecainide for chronic therapy of PSVT. Small numbers of pts w/ PSVT, n
2015_SVT_Evidence_Tables_Data_Supplement.docx